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Despite concerted research efforts, prevention and
treatment of graft-versus-host disease (GVHD) have not
changed signiﬁcantly over the past 3 decades. The goal of this
session is to provide an outline of the current state of the
science with respect to the prevention, treatment, and
evaluation of acute and chronic GVHD. In addition, we detail
those strategies most likely to be at the forefront of clinical
research in the upcoming years.
PREVENTION OF GVHD: RECENT DEVELOPMENTS AND
FUTURE TRIALS
A calcineurin inhibitor (CNI) combined with a short
course of methotrexate (MTX) is the most common GVHD
prophylaxis regimen used in myeloablative or reduced-
intensity conditioning (RIC) transplants, whereas a CNI
combined with mycophenolate mofetil (MMF) is the
most frequent regimen in nonmyeloablative conditioned or
umbilical cord transplants. Recently, the Blood and Marrow
Transplant Clinical Trials Network (BMT CTN) completed
a Phase III trial comparing the mammalian target of rapa-
mycin inhibitor sirolimus combined with tacrolimus and
tacrolimus/MTX in matched related donor graft recipients
receiving ablative conditioning. Accrual for patients
receiving busulfan conditioning was closed early owing to
a higher incidence of veno-occlusive disease of the liver in
the sirolimus arm, thus limiting the applicability of the
results from this trial [1].
Moving forward, there has been awealth of single-center,
early-phase trials examining novel GVHD prevention strat-
egies that potentially warrant evaluation in larger, multi-
center trials. The current challenge is to select the most
promising of these approaches. Before we review these
“newer” strategies, 2 “older” approachesdex vivo and in vivo
T cell depletion (TCD)dwarrant brief discussion.
TCD
Ex Vivo TCD
Historically, techniques for ex vivo TCD have varied,
resulting in inconsistent reductions in T cells. Modern
methods for ex vivo TCD (CD34 selection) using magnetic
bead columns result in consistent reductions of T cells by 4-5
logs [2]. Recently, patients with acute myelogenous leukemiaFinancial disclosure: See Acknowledgments on page S107.
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(MSKCC) were compared with patients receiving T celle
replete transplants at M.D. Anderson Cancer Center [3]. The
majority of patients at MSKCC received ablative conditioning,
with ex vivo TCD (CD34 selection) used as sole GVHD
prophylaxis. All the patients at M.D. Anderson received
busulfan and ﬂudarabine conditioning combined with
tacrolimus/MTX. Patient characteristics were comparable in
the 2 groups, except that theMSKCC cohort was slightly older
(Table 1).
The ﬁndings from this analysis challenge some previously
held conceptions regarding the beneﬁts and limitations of
these 2 approaches. Not surprisingly, acute and chronic
GVHD rates were lower in recipients of ex vivo TCD grafts;
however, surprisingly, this did not translate into lower
nonrelapse mortality (NRM). Equally surprising, relapse rates
were not better in patients receiving T cellereplete trans-
plants. Thus, overall survival (OS) rates were comparable in
the 2 cohorts (Table 2). Similar results were seen in a BMT
CTN analysis comparing outcomes for patients on a phase II
trial of ex vivo TCD transplantation and patients who
received a T cellereplete transplant on an earlier trial [2].
In Vitro TCD
Incorporation of T celledepleting antibodies in vivo is
another commonly used method to lower GVHD rates. In an
international study, Fresenius antithymocyte globulin (ATG)
was found to lower rates of grade II-IV acute GVHD and
chronic GVHD after ablative conditioning, with no impact on
relapse [4]. Based on this ﬁnding, a licensing study is
currently underway in the United States. Although these
studies may deﬁne the role of antieT cell antibodies in the
ablative setting, the utility of ATG in nonmyeloablative or RIC
transplantations remains unclear. A recent analysis suggests
that in nonmyeloablative or RIC transplantions, the reduced
rates of GVHD may be offset by higher rates of relapse [5].
Novel GVHD Prophylaxis Trials
Four recently published primarily single-center GVHD
prevention trials have yielded encouraging results and
warrant consideration for future multicenter trials. These 4
trials entailed the study of pentostatin, cyclophosphamide,
bortezomib, and maraviroc for GVHD prophylaxis (Figure 1).
Pentostatin
Researchers at M.D. Anderson Cancer Center have studied
the addition of the nucleoside analog pentostatin to GVHD
prophylaxis with CNI/MTX in matched unrelated or mis-
matched allogeneic transplant recipients [6]. A total of 147Society for Blood and Marrow Transplantation.
Table 1
Characteristics of Recipients of Ex Vivo T CelleDepleted Transplants at Memorial Sloan Kettering Cancer Center and T CelleReplete Transplants at M.D. Anderson
Cancer Center
MSKCC; Ex Vivo T Cell Depletion M.D. Anderson; T Cell
Replete (Tacrolimus/MTX)
P Value
Number 115 181
Follow-up, days, median (range) 32 (1-108) 29 (2-104)
Diagnosis, n (%)
De novo acute myelogenous leukemia 60 (52) 144 (80) <.001
Acute myelogenous leukemia from myelodysplastic syndrome 38 (33) 24 (13)
Therapy-related acute myelogenous leukemia 17 (15) 13 (7)
Time from diagnosis to transplantation, days, median (range) 140 (59-1605) 155 (57-532) .08
Age, years, median (range) 52 (19-71) 48 (18-63) .0001
Cytogenetic risk, n (%)
Favorable 1 (1) 2 (1) .30
Intermediate 72 (63) 103 (57)
Poor 42 (37) 76 (42)
Conditioning regimen, n (%)
Busulfan þ ﬂudarabine (rabbit ATG for matched unrelated donors) 0 (0) 181 (100)
Busulfan þ ﬂudarabine þ melphalan 61 (53)
Total body irradiation þ thiotepa þ Cy or ﬂudarabine 54 (47)
Donor type, n (%)
Matched related 56 (49) 103 (57) .20
Matched unrelated 32 (28) 64 (35)
1 or 2 antigen MM related/unrelated 27 (23) 14 (8)
HLA matching, n (%)
10/10 88 (77) 167 (92) <.001
9/10 23 (20) 14 (8)
8/10 4 (3) 0 (0)
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mens were enrolled onto this Bayesian, adaptively random-
ized, controlled phase I/II trial. The majority of patients also
received low-dose rabbit ATG. The results of that study show
that pentostatin at a dose of 1.5 mg/m2/week for 4 weeks
resulted in the highest fraction of patients alive and GVHD-
free at day 100 posttransplantation with no previous grade
III-IV acute GVHD compared with the control arm. The rate of
grade III-IV acute GVHD for this armwas 10.7%, with no cases
seen in HLA-mismatched transplant recipients.
Cyclophosphamide
Researchers at Johns Hopkins University have examined
posttransplantation cyclophosphamide (Cy) as a sole GVHD
prophylaxis strategy based onmurinemodels demonstrating
effective depletion of alloreactive T cells through the use of
pulsed doses of Cy in the early posttransplantation period.
Results of a Phase II trial of posttransplantation Cy in 117
recipients of matched related and unrelated bone marrow
grafts after ablative conditioning with busulfan/Cy demon-
strated a rate for acute GVHD grade II-IV (43%; 95% conﬁ-
dence interval [CI], 34%-52%) comparable to that for
traditional prophylaxis regimens, whereas the rate for
chronic GVHD was lower (10%; 95% CI, 5%-16%) [7].
Posttransplantation Cy as the sole GVHD prophylaxis seemsTable 2
Comparison of Recipients of Ex VivoT Cell Transplants at Memorial Sloan Kettering C
MSKCC; Ex Vivo T Cell Depletion
(n ¼ 115), % (95% CI)
M.D. A
(n ¼ 18
Acute GVHD II-IV at day 100 5 (2-11) 18 (13
Chronic GVHD at 3 years 13 (8-22) 53 (46
NRM
Day 100 8 (4-15) 3 (1-7
3 year 24 (17-34) 16 (11
PFS at 3 years 18 (12-27) 25 (19
OS at 3 years 57 (47-67) 66 (58to be beneﬁcial after ablative conditioning, but not after
RIC. A recent Phase II study at M.D. Anderson using
this strategy with RIC demonstrated higher rates of acute
GVHD compared with a matched cohort of recipients
who received standard GVHD prophylaxis, suggesting that
posttransplantation Cy may need to be combined with
additional drugs when used with a less-intensive condi-
tioning regimen (Table 3) [8]. In support of this, a study of
the addition of posttransplantation Cy to tacrolimus/MMF
GVHD prophylaxis in recipients of T cellereplete bone
marrow grafts from haploidentical donors after non-
myeloablative conditioning demonstrated a 34% incidence of
grade II-IV acute GVHD and a 5% incidence of extensive
chronic GVHD [9].
Bortezomib
The Dana-Farber Cancer Institute evaluated the addition
of the proteasome inhibitor bortezomib to tacrolimus/MTX
prophylaxis on days 1, 4, and 7 posttransplantation in 45
recipients of a 1 or 2 antigen-mismatched, T cellereplete,
unrelated peripheral blood transplantations after RIC [10].
This Phase I/II study found a 22% (95% CI, 16%-34%) day 180
incidence of grade II-IV acute GVHD and a 29% (95% CI,
16%-43%) 1-year incidence of chronic GVHD, which are
comparable to rates in a contemporaneous cohort ofancer Center and T CelleReplete Transplants at M.D. Anderson Cancer Center
nderson; T Cell Replete (Tacrolimus/MTX)
1), % (95% CI)
HR (95% CI) P Value
-24) 3.9 (1.5-9.9) .005
-62) 4.6 (2.6-8.1) <.001
) 0.4 (0.1-1.1) .07
-23) 0.6 (0.3-1.1) .10
-33) 1.3 (0.8-2.3) .30
-74) 0.7 (0.5-1.1) .20
Table 3
Matched Cohort Analysis of Tacrolimus/Methotrexate versus Posttransplantation Cyclophosphamide after RIC
Posttransplantation CY (n ¼ 49), % (95% CI) Tacrolimus and Methotrexate, % (95% CI) HR (95% CI) P Value
Acute GVHD grade II-IV 46 (32-66) 19 (10-37) 2.8 (1.1-6.7) .02
Chronic GVHD at 1 year 14 (6-32) 21 (11-43) 0.8 (0.2-2.6) .70
NRM at 2 years 36 (23-55) 16 (7-35) 2.4 (0.8-6.7) .10
PFS at 2 years 22 (10-37) 33 (16-51) 1.3 (0.7-2.3) .40
OS at 2 years 26 (13-42) 46 (26-64) 1.8 (0.9-3.3) .08
A.M. Alousi et al. / Biol Blood Marrow Transplant 19 (2013) S102eS108S104matched unrelated donor graft recipients who received
sirolimus-based GVHD prophylaxis at their institution.
The results of that trial suggest that immune modulation
with bortezomib may reduce GVHD (and consequently
NRM) in what is otherwise a high-risk, HLA-mismatched
population.
Maraviroc
Another novel approach targeting T cell trafﬁcking using
the chemokine 5 receptor antagonist maraviroc was recently
studied in a Phase I/II trial at the University of Pennsylvania
[11]. Thirty-eight patients received a matched related or
unrelated peripheral blood transplant after RIC, and then
received maraviroc along with tacrolimus/MTX from day þ2
to day þ30 posttransplantation. Mean rates of day 100 and
day 180 grade II-IV acute GVHD were 14.7%  6.2% and
23.6%  7.4%, respectively, with low rates of visceral GVHD
(liver, 2.9%  2.9%; gut, 8.8%  5%). These clinical results
appear to be consistent with murine models demonstrating
the ability of CCR5 blocking antibodies to ameliorate visceral
GVHD. However, the occurrence of late acute GVHD suggests
that a longer duration of drug therapy may be needed.
Future Studies: BMT CTN GVHD Prophylaxis Trial
Differing study populations and trial endpoints make
direct comparison of the foregoing studies problematic. In an
effort to objectively evaluate each of these trials, the GVHD
State-of-the-Science Committee of the BMT CTN recently
conducted a benchmark analysis to determine the most
promising prophylaxis regimens to move forward into
a multicenter trial. Datasets from each of the 4 aforemen-
tioned trials, along with an ex vivo TCD dataset fromMSKCC,
were individually matched to controls within the Center for
International Blood and Marrow Transplant Research
(CIBMTR) who received CNI/MTX prophylaxis. The ﬁndingsTable 4
Results from a Benchmark Analysis Comparing CIBMTR Matched Controls
with GVHD Prophylaxis Strategies: Pentostatin, Cy, Maraviroc, Bortezomib,
and Ex Vivo T Cell Depletion
Measured Outcomes Proposals Statistically Better Than
Their CIBMTR Matched Controls
Acute GVHD grade II-IV  Ex vivo T cell depletion
 Bortezomib
Acute GVHD grade III/IV  Ex vivo T cell depletion
 Pentostatin
Chronic GVHD  Ex vivo T cell depletion
 Pentostatin
 Posttransplantation Cy
DFS  Ex vivo T cell depletion
 Pentostatin
OS  Ex vivo T cell depletion
 Bortezomib
 Pentostatin
Conclusions of benchmark analysis: Each proposal was the same or better
than the CIBMTR matched controls receiving standard GVHD prophylaxis.from this analysis are summarized in Table 4. Based on this
information, along with an “assessment of interest” deter-
mined through a survey of core centers, a decisionwas made
to proceed with a randomized Phase II trial comparing
posttransplantation Cy/tacrolimus/MMF, bortezomib/tacro-
limus/MTX, and maraviroc/tacrolimus/MTX in recipients of
matched or 1 antigen-mismatched unrelated donor trans-
plants after RIC (Figure 2). Each arm will be compared to
a prospectively matched cohort of patients in the CIBMTR.
GVHD and relapse-free survival at 1 year will be the primary
endpoint.
TREATMENT OF ACUTE GVHD: LESSONS LEARNED FROM
BMT CTN 0302 AND 0802
The current standard therapy for acute GVHD is steroids;
however, durable responses are not the rule [12-14].
Although other agents have been added to steroids in the
past, the combinations have failed to show an advantage,
owing to excess toxicity or lack of superior control [15,16].
Here we review 2 recent multicenter trials of up-front
therapy for acute GVHD.
BMT CTN 0302
BMT CTN 0302 was a 4-arm, randomized Phase II trial
that evaluated the 4 drugs etanercept, MMF, denileukin dif-
titox, and pentostatin each in combination with steroids
for patients with newly diagnosed acute GVHD [17]. A
randomized Phase II studywas chosen as an efﬁcient method
for selecting the most promising combination for a larger
Phase III trial [18]. A total of 180 patients were randomized
to the 4 study arms, with patients receiving MMF for
GVHD prophylaxis randomized to a non-MMF arm. Day 56
complete response rates were 44% for etanercept, 73% for
MMF, 55% for denileukin diftitox, and 62% for pentostatin.
Corresponding 9-month OS rates were 47%, 64%, 49%, and
47%. The cumulative incidence of grade 3 or greater infec-
tions at day 270 was lowest in the MMF arm. Given that
efﬁcacy, survival, and toxicity all favored MMF, MMF was
selected as the most promising therapy to be combined with
steroids in a randomized, double-blinded, Phase III trial.
What Else Was Learned from 0302?
Pharmacokinetic analyses showed that approximately
one-half of subjects did not achieve targetmycophenolic acid
(MPA) total and unbound trough concentrations. Therefore,
administration of MMF 1 g twice daily as on BMT CTN 0302
produced low plasma concentrations in many patients [19].
MPA pharmacokinetic measurements from weeks 1 and 2
did not correlate with complete responses at either day 28 or
day 56. In contrast, patients with mean total MPA troughs
of>0.5 mg/mL or unbound troughs of>0.015 mg/mL at weeks
1 and 2 had signiﬁcantly greater proportions of complete and
partial responses at days 28 and 56, suggesting the need for
a higher dose of MMF [19]. Levine et al. [20] examined
time to maximum response as a predictor for long-term
Figure 1. Schema of 4 novel GVHD prophylaxis regimens. (A) Pentostatin with tacrolimus/MTX. (B) Cyclophosphamide with or without tacrolimus/MMF.
(C) Bortezomib with tacrolimus/MTX. (D) Maraviroc with tacrolimus/MTX.
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Figure 2. BMT CTN GVHD Prophylaxis Trial: randomized Phase II with CIBMTR matched controls.
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acute GVHD treatment was used to categorize patients for
NRM and survival. Day 28 response (complete or partial) best
predicted NRM and survival at 9 months from the start of
acute GVHD treatment. Levine et al. [21] also examined
a panel of biomarkers initially identiﬁed at the University of
Michigan by Paczesny et al. [22], including IL-2 receptor-a,
tumor necrosis factor receptor 1, hepatocyte growth factor,
IL-8, elaﬁn, and regenerating islet-derived 3-a, to discrimi-
nate responders from nonresponders. Biomarkers measured
on days 0, 14, and 28 were found to predict for day 28
posttherapy nonresponse and day 180 mortality [21].
BMT CTN 0802
This Phase III, double-blinded, randomized trial
compared steroids/MMF and steroids/placebo. One notable
difference between trial 0302 and trial 0802 was the use of
an increased dose of MMF (1 g every 8 hours) based on the
pharmacokinetic data from 0302 [19]. The primary study
endpoint was GVHD-free survival at day 56. (The analysis of
Levine et al. [20] demonstrating the signiﬁcance of day
28 response was not yet available at the time the protocol
was written.) Enrolled patients with any grade of newly
diagnosed acute GVHD were started on prednisone at
2 mg/kg/day alongwithMMF or placebo. Tapering of steroids
could commence after 3 days at the discretion of the treating
physician, but all patients were required to receive
a minimum of 0.25 mg/kg/day of prednisone on day 28.
MMF/placebo was continued until day 56 or until steroid
discontinuation, whichever came ﬁrst.
The study was terminated early when a “futility rule”
was met at a planned interim analysis following the
enrollment of 236th (out of 372 planned) patient. A total of
117 patients were randomized to MMF and 119 patients
were randomized to placebo at 36 participating centers. The
2 groups were well balanced in terms of patient character-
istics. The distribution of acute GVHD grades at randomi-
zation was 65% I/II, 28% III, and 6% IV. GVHD-free survival atday 56 after randomization was 60.5% (95% CI, 51.6%-69.5%)
for MMF (69 patients) and 52.2% (95% CI, 43%-61.3%) for
placebo (60 patients) (P ¼ .78). Chronic GVHD developed in
38 patients in the MMF arm (6-month estimate, 23.7%; 95%
CI, 15.9%-31.6%) and in 39 patients in the placebo arm (6-
month estimate, 26.5%; 95% CI, 18.3%-34.7%) (P ¼ .69). OS
at 6 months, rate of Epstein-Barr virus reactivation, and
cumulative incidence of grade 3 infections were similar in
the 2 arms, as were toxicity patterns. The cumulative inci-
dence estimate for NRM at 6 months also was similar in the
2 arms: 15.5% for MMF and 20.1% for placebo (P ¼ .83). The
estimated 6-month OS was 71% for MMF and 73% for
placebo (P ¼ .25).
Four Hundred and Sixteen Patients Later, What Was
Learned?
In the last decade, the BMT CTN conducted 2 randomized
clinical trials evaluating acute GVHD therapies involving
a total of 416 patients. At the end, steroid alone remains the
ﬁrst-line therapy. BMT CTN 0302 and 0802 have taught us
many things: multicenter clinical trials for acute GVHD are
possible (and encouraged); a large proportion of clinicians
treat patients with grade I acute GVHD; MMF dosing is
often subtherapeutic when given every 12 hours; day 28
response is predictive of NRM and OS; biomarkers may be
able to discriminate patients who will respond from those
who will not; and, most importantly, additional immuno-
suppression with MMF did not improve outcomes for our
patients [17,19-21]. Actually, given the diversity of trans-
plantation regimens and the genetic uniqueness of each
donorerecipient pair, the remarkable ﬁnding is that steroids
continue to have such a high response rate. The development
of a "magic bullet" able to control all of the diverse immune
responses that we read clinically as acute GVHD is unlikely.
The challenge for the future is to improve biomarkers to the
point at which trials can be designed that individualize
treatment assignments based on the likelihood for GVHD
response (and, conversely, NRM and survival). In such a way,
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for future phase I/II trials.CHRONIC GVHD: DO WE KNOW HOW TO MEASURE
SEVERITY AND RESPONSE?
NIH Consensus Conference
Chronic GVHD affects 30%-50% of allogeneic hematopoi-
etic cell transplantation (HCT) survivors and is a major cause
of morbidity and mortality. In 2004, Pavletic and Vogelsang,
with support from the National Cancer Institute, Ofﬁce of
Rare Diseases Research, Department of Defense, National
Heart, Lung and Blood Institute, Health Resources and
Services Administration, and the National Institute of Allergy
and Infectious Diseases, convened a Consensus Conference
with the goal of advancing research in chronic GVHD.
Participants in this Consensus Conference wrote 6 papers to
provide the recommendations for diagnosis and scoring [23],
pathology [24], biomarkers [25], response criteria [26],
supportive care [27], and design of clinical trials [28].
Before the Consensus Conference, criteria for the diag-
nosis of chronic GVHD had not been codiﬁed. Severity
grading was dichotomous, with 2 broad categories of
“limited” and “extensive” that were often erroneously
interpreted to mean “not so bad” and “bad.” Outcomes of
clinical trials were based on clinician assessment of
response: complete response (complete resolution of chronic
GVHD), partial response (>50% improvement in at least one
organ with no worsening in any other), stable disease,
progression, or mixed response (improvement in one organ
but worsening in another). Lack of objective data to support
the clinician response assessments made it very difﬁcult to
have conﬁdence in reported results or to compare agents
tested in different trials. Phase II studies routinely reported
very high response rates, whereas daily clinical experience
did not seem to conﬁrm the positive reports.
Major recommendations from the Consensus Conference
included (1) a strict set of diagnostic criteria for chronic
GVHD that no longer depends on time after HCT; (2) recog-
nition of “overlap” syndrome when concurrent acute and
chronic GVHD are active; (3) a 0-3 scoring system for severity
in 8 organs; (4) an algorithm for calculating global severity
based on individual organ scores of 0-3; and (5) a set of
response criteria for skin, eye, mouth, upper gastrointestinal,
esophagus, lower gastrointestinal, liver, and lung that
includes scales and methods of calculating responses. Tools
for capturing patient-reported outcomes and functional
capacity were recommended as well. The conference was
well attended, and clinicians and investigators have started
to use these deﬁnitions and materials widely. However, most
recommendations were based on consensus rather than
data. In the 6 years since the publication of the Consensus
criteria, do we have evidence of their validity?What Have We Learned from the Longitudinal Study?
Data from a prospective multicenter observational study
suggest that the severity scoring recommendations are valid
and are able to segregate patients with chronic GVHD into 3
global severity groups (mild, moderate, and severe) with
differing symptom burdens, quality of life, risks of NRM, and
survival [29-31]. Additional studies that evaluated organs
individually found that the severity scoring systemwasmore
valid and sensitive to change compared with the response
measures [32,33]. These results suggest that the 0-3 scoring
system and global severity score may be used withconﬁdence to describe the current burden of chronic GVHD
in a population, as well as an endpoint in prophylaxis trials.
Two recent studies examined the proposed response
criteria, scoring the scales as recommended in a supplement
to the original article [34,35]. Those studies suggested that
the response categories do not correlate with clinician or
patient perceptions of response to treatment and do not
predict NRM or OS [34,35]. Thus, the response criteria as
currently formulated are not adequate endpoints for clinical
trials. How should we solve this problem? Onewaywould be
to start over from scratch, substituting instruments or
designing new ones. Alternatively, members of the Chronic
GVHD Consortium believe that there may be a way to work
with the currently recommended scales by using different
methods of aggregating the organ system measures or
applying a new way of calculating responses [36]. However,
much work remains to be done to design and validate
response measures.
BMT CTN 0801
In 2010, the BMT CTN launched the largest intervention
study for patients with chronic GVHD yet attempted
(n ¼ 300). This Phase II/III trial, designed to overcome
previous limitations of single-center participation and small
numbers, is collecting all of the recommended instruments
of the NIH Chronic GVHD Consensus Conference. Initially
launched as parallel, randomized Phase II studies
comparing prednisone/sirolimus/CNI with prednisone/siro-
limus or prenisone/sirolimus/extracorporeal photopheresis,
the second Phase II study was dropped in 2011 owing to slow
accrual. However, the remaining 2 arms have been achieving
target accrual, and the Phase II portion of the study is
scheduled to complete enrollment in early 2013. If the early
results, based on clinician-reported complete plus partial
responses at 6 months, look promising, the study will
proceed to the larger Phase III. The primary endpoint of the
Phase III study is resolution of all reversible manifestations of
chronic GVHD at 2 years after study entry, a "hard" endpoint
that is less susceptible to physician bias.
In summary, the lack of validated response measures is
the greatest barrier to the design of future intervention
studies, especially those that will include patients with
heterogeneous chronic GVHD manifestations. We simply do
not have the objective tools to be able to conﬁrm a physi-
cian’s or patient’s impression of response or progression, nor
do we have validated biomarkers or alternate ways of iden-
tifying patients responding to treatment. BMT CTN 0801
should be informative because it is protected from being
uninterpretable because of the hard endpoint selected for
the Phase III trial, but most chronic GVHD trials will not have
the luxury of large numbers and 2-year endpoints. To make
progress and prepare for the day when we do have better
potential therapies for chronic GVHD, a focus on developing
robust response measures is needed.
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